#ICYMI Gain Therapeutics Interim CEO Gene Mack speaks with Ram Selvaraju at H.C. Wainwright & Co., LLC’s Annual Neuro Perspectives Virtual Conference https://lnkd.in/eehbxZzH
Gain Therapeutics’ Post
More Relevant Posts
-
🌟 Friday Read: Accelerating Drug Development with Spatial Biology 👉https://bit.ly/4aro6Lo Presage Biosciences, Inc.'s CIVO® platform, combined with GeoMx and CosMx technologies, effectively tracks anti-neoplastic and immune-modulating activity in the intact tumor microenvironment. This innovative approach is speeding up drug development and paving the way for more successful clinical trials.🔬 #SpatialBiology #DrugDevelopment #FridayRead This post may include information regarding CosMx™ SMI products for RNA detection, which products are not available in the Federal Republic of Germany, as further described here - https://lnkd.in/gUXh88Pr.
To view or add a comment, sign in
-
Helix's CEO, Mr. Josh Carter, is actively engaging at the American Crystallographic Association's 74th Annual Meeting in Denver, Colorado, from July 7-12, 2024. Day three has been electrifying, featuring an array of exciting and highly relevant topics such as MicroED, Cryo-EM, and Structural Biology in Pharma/Biotech. Two great talks that highlight the intersection of various disciplines, including crystallization, docking, and targeting undruggable proteins, are "Novel Fragment Inhibitors of PYCR1 from Docking-Guided X-ray Crystallography" from U. Missouri, ChemSpace, and Taras Shevchenko National University of Kyiv, and "Branched Chain Ketoacid Dehydrogenase Kinase Inhibitors: From Fragments to Clinical Candidate" by Pfizer. And don’t miss the poster sessions, which are also full of groundbreaking research! Mr. Josh Carter looks forward to connecting with both familiar and new friends, clients, and colleagues, sharing Helix's contributions and insights on today's topics in these fields. Be sure to catch up with him! Did you know... Our leading Cryo-EM services, together with our extensive expertise, consistently fuel the success of our clients and their projects? Empower projects with Helix and Cryo-EM. Call us today! (https://loom.ly/SNcIRks) #cryoem #crystallization #crystallography #drugdiscovery #drugdesign #protein #proteins #dna #rna #antibody #antibodies #science #nature #research #bio #bionetwork #biotechnology #biotech #bioscience #biotechnologyindustry #biopharma #drugdesign #drugdevelopment #pharmaceuticals #pharma #drug #lifesciences #lifescience
Accelerating Drug Discovery | Helix BioStructures
helixbiostructures.com
To view or add a comment, sign in
-
EditCo Bio & Saha Lab Collaboration Breakdown: The study demonstrates the efficient production of primary human T cells with simultaneous CRISPR/Cas9-mediated knockout of three genes (B2M, TRAC, PD1) and non-viral transfection of a CAR targeting GD2. The resulting TRAC-B2M-PD1-deficient GD2 CAR T cells show high cytotoxicity against neuroblastoma cells, retain a central memory phenotype, and exhibit low off-target effects and chromosomal alterations. This approach highlights the potential for rapid, safe, and efficient manufacturing of potent allogeneic CAR T-cell products.
To view or add a comment, sign in
-
How do you program "intelligent" cells for applications in biocomputation and living therapeutics? Check out our latest publication to learn more (https://lnkd.in/e5V2FGSq). -We combined recombinase-based MEMORY circuits with transcriptional programs and intercellular communication in a single platform -An orthogonal array of inducible recombinases integrated into the genome mediates diverse DNA recombination events -Programmable CRISPR-dCas9 protection of DNA enables advanced control over recombinase activity -Intercellular communication + MEMORY circuits allow for programmed information exchange between microbes Thanks to help from Dowan Kim and Yongjoon Yu at Georgia Institute of Technology!
To view or add a comment, sign in
-
GOLD in Action⭐ In the highlighted publication, the mechanism of action of the mGlu7 receptor antagonist XAP044 was elucidated by combining a structure‒activity relationship study, molecular modeling and docking experiments. The team performed docking studies using the CCDC's protein-ligand docking software GOLD, integrated within Dassault Systèmes’ BIOVIA therapeutics design software #DiscoveryStudio. 🔗https://lnkd.in/e5qVdJ67 #GOLD #docking
To view or add a comment, sign in
-
Our CEO, Tuyen Ong, MD, MBA, was featured in the latest episode of the Biotech2050! Hear Tuyen dive into his career journey and share insights on the importance of cross-disciplinary expertise and resilience in transforming the future of #GeneticMedicine.
Interested in the future of precision medicine? Join Rahul Chaturvedi for an in-depth conversation with Tuyen Ong, CEO of Ring Therapeutics & CEO-Partner at Flagship Pioneering, as we dive into the disruptive potential of genetic medicine and overcoming delivery challenges. Listen to the episode: https://t.ly/eNPyy #biotech #precisionmedicine #genetherapy
To view or add a comment, sign in
-
Are you attending the 29th Annual Meeting #RNA2024 of the The RNA Society in Edinburgh, Scotland? Don't miss Anahi Higuera´s poster presentation titled "Time-Dependent Binding of Molecules and Influence on RNA Modification: From Proteins to RNA-Based Therapeutics." Join Anahi to explore #switchSENSE, a cutting-edge biophysical technique for characterizing #RNA-binding proteins, nucleic acid aptamers, and antisense oligonucleotides. Connect with us on-site to dive into the world of molecular interactions and #drugdiscovery! #DiscoverMolecularInteractions
To view or add a comment, sign in
-
TCO PEG Linkers are bioorthogonal agents for tetrazine. The cycloaddition reaction between tetrazine and trans-cyclooctene (TCO) is rapidly growing in use for bioconjugation, molecular imaging and cell-based diagnostics. The chemoselective TCO–Tz ligation pair possess ultrafast kinetics unmatched by any other bioorthogonal ligation pair. https://lnkd.in/gpynRz-p #Bioanalysis #AxisPharm #lab #labservice #cro #adctechnology #drugdevelopment #metabolomics #Proteomics #drugformulation #protein
To view or add a comment, sign in
-
The Discovery on Target is starting next week in Boston! And no matter what your target is, we have the matching biophysical assay for you in store to investigate binding of molecules to your target in real time. Whether it’s ❔ #PROTACs and #molecularglues ❔ #smallmolecules targeting RNA or proteins ❔ transmembrane targets like #GPCRs ❔ #antibodies ❔ #transcription factors ❔ or something else ❗ Come to booth no.318 to find out how to characterize molecule-molecule interactions in superior detail with #switchSENSE or how to measure cell-molecule interactions with Real-Time Interaction Cytometry (#RTIC). Antonio Di Meco and Ulrich Rant are happy to discuss specific applications with you! #BostonDOT23 #DiscoverMolecularInteractions
Meet us at booth #318 at Discovery on Target in Boston, September 25-28!
discoveryontarget.com
To view or add a comment, sign in
-
Looking forward to #SLAS2024 where we will be showcasing our ioCRISPR-Ready Cells™️ products. Our poster presentations will include data from two products - the recently launched CRISPR-Ready ioGlutamatergic Neurons™️ and the next product in the range - CRISPR-Ready ioMicroglia™️. Find out more in the press release. 👇📰 https://hubs.ly/Q02j60Vz0 ioCRISPR-Ready Cells are iPSC-derived human cells containing a constitutively-expressed Cas9 nuclease. They arrive ready-to-use and with simple protocols, allowing high gene knockout efficiencies and functional experimental readouts in a physiological relevant cellular model in days, significantly reducing experimental timelines. #CRISPR #Research #DrugDevelopment #SynBio #BioEngineering
bit.bio to showcase its ioCRISPR-Ready Cells™️ products at SLAS 2024
bit.bio
To view or add a comment, sign in
4,637 followers